These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19023151)

  • 1. Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention.
    Kato R; Momiyama Y; Ohmori R; Tanaka N; Taniguchi H; Arakawa K; Nakamura H; Ohsuzu F
    Circ J; 2009 Jan; 73(1):152-7. PubMed ID: 19023151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention.
    Momiyama Y; Ohmori R; Uto-Kondo H; Tanaka N; Kato R; Taniguchi H; Arakawa K; Nakamura H; Ohsuzu F
    J Atheroscler Thromb; 2011; 18(2):108-14. PubMed ID: 21071880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Joint effects of N-terminal pro-B-type-natriuretic peptide and C-reactive protein vs angiographic severity in predicting major adverse cardiovascular events and clinical restenosis after coronary angioplasty in patients with stable coronary artery disease.
    Dai DF; Hwang JJ; Lin JL; Lin JW; Hsu CN; Lin CM; Chiang FT; Lai LP; Hsu KL; Tseng CD; Tseng YZ
    Circ J; 2008 Aug; 72(8):1316-23. PubMed ID: 18654020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.
    Ari H; Ari S; Erdoğan E; Tiryakioğlu O; Ustündağ Y; Huysal K; Koca V; Bozat T
    Heart Vessels; 2010 Jan; 25(1):19-26. PubMed ID: 20091394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of osteopontin before and 24 h after percutaneous coronary intervention.
    Georgiadou P; Iliodromitis EK; Kolokathis F; Mavroidis M; Andreadou I; Demopoulou M; Varounis Ch; Capetanaki Y; Boudoulas H; Kremastinos DT
    Expert Opin Ther Targets; 2008 Dec; 12(12):1477-80. PubMed ID: 19007317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of multiple biomarkers in stable patients undergoing fractional flow reserve-guided coronary angioplasty.
    Fracassi F; Niccoli G; Scalone G; Di Gioia G; Conte M; Bartunek J; Sgueglia GA; De Bruyne B; Montone RA; Wijns W; Crea F; Barbato E
    J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):687-93. PubMed ID: 26627500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein plasma levels but not factor VII activity predict clinical outcome in patients undergoing elective coronary intervention.
    Grander W; Dichtl W; Prokop W; Roithinger FX; Moes N; Friedrich G; Weidinger F; Pachinger O
    Clin Cardiol; 2004 Apr; 27(4):211-6. PubMed ID: 15119695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteopontin plasma levels and accelerated atherosclerosis in patients with CAD undergoing PCI: a prospective clinical study.
    Mazzone A; Parri MS; Giannessi D; Ravani M; Vaghetti M; Altieri P; Casalino L; Maltinti M; Balbi M; Barsotti A; Berti S
    Coron Artery Dis; 2011 May; 22(3):179-87. PubMed ID: 21407077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic value of plasma brain natriuretic peptide and C-reactive protein in patients with acute coronary syndromes underwent percutaneous coronary intervention].
    He B; Ding S; Pu J; Liu JP; Song W; Du YP; Shen JY; Jin SX; Sun Y; Shen L
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Apr; 34(4):349-52. PubMed ID: 16776932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement.
    Rittersma SZ; de Winter RJ; Koch KT; Schotborgh CE; Bax M; Heyde GS; van Straalen JP; Mulder KJ; Tijssen JG; Sanders GT; Piek JJ
    Clin Chem; 2004 Sep; 50(9):1589-96. PubMed ID: 15205368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions.
    Kubica J; Kozinski M; Krzewina-Kowalska A; Zbikowska-Gotz M; Dymek G; Sukiennik A; Piasecki R; Bogdan M; Grzesk G; Chojnicki M; Dziedziczko A; Sypniewska G
    Int J Mol Med; 2005 Jul; 16(1):173-80. PubMed ID: 15942695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneous coronary intervention.
    Jeong WK; Jeong MH; Kim KH; Lee SR; Park OY; Yum JH; Kim JH; Kim W; Rhew JY; Ahn YK; Cho JG; Ahn BH; Suh SP; Park JC; Kim SH; Kang JC
    Korean J Intern Med; 2003 Sep; 18(3):154-60. PubMed ID: 14619384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis.
    Ishii H; Toriyama T; Aoyama T; Takahashi H; Amano T; Hayashi M; Tanaka M; Kawamura Y; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
    Circ Cardiovasc Interv; 2009 Dec; 2(6):513-8. PubMed ID: 20031768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention.
    Bjerre M; Pedersen SH; Møgelvang R; Lindberg S; Jensen JS; Galatius S; Flyvbjerg A
    Eur J Prev Cardiol; 2013 Dec; 20(6):922-9. PubMed ID: 23613225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention.
    Kardys I; Oemrawsingh RM; Kay IP; Jones GT; McCormick SP; Daemen J; Van Geuns RJ; Boersma E; Van Domburg RT; Serruys PW
    Clin Cardiol; 2012 Aug; 35(8):482-9. PubMed ID: 22488248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between plasma pregnancy-associated plasma protein a and restenosis after percutaneous coronary angioplasty.
    Li XP; Zhou SH; Tang JJ; Liu QM; Fang ZF; Hu XQ; Zhou T; Sheng XQ; Zhao SP
    Circ J; 2008 May; 72(5):729-33. PubMed ID: 18441451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma osteopontin concentration is elevated in patients with coronary bare metal stent restenosis.
    Yilmaz KC; Bal UA; Karacaglar E; Okyay K; Aydinalp A; Yildirir A; Muderrisoglu H
    Acta Cardiol; 2018 Feb; 73(1):69-74. PubMed ID: 28841817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events and restenosis in patients undergoing coronary stent implantation: a prospective study.
    Akcakoyun M; Kargin R; Tanalp AC; Pala S; Ozveren O; Akcay M; Barutcu I; Kirma C
    Coron Artery Dis; 2008 Aug; 19(5):337-43. PubMed ID: 18607171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation.
    Park DW; Lee CW; Yun SC; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Heart; 2007 Sep; 93(9):1087-92. PubMed ID: 17309906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study.
    Georgiadou P; Iliodromitis EK; Kolokathis F; Varounis C; Gizas V; Mavroidis M; Capetanaki Y; Boudoulas H; Kremastinos DT
    Eur J Clin Invest; 2010 Apr; 40(4):288-93. PubMed ID: 20192976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.